January 23, 2018

The implementation of the next Texas Medicaid Preferred Drug List (PDL) has been delayed until Thursday, Feb. 1, 2018, and will include only those changes approved at the Jul. 28, 2017, Drug Utilization Review (DUR) Board meetings.  There will be a follow-up implementation at a later date to deploy those changes recommended at the Nov. 3, 2017, DUR board meeting.

The table below summarizes noteworthy changes from the Jul. DUR Board meeting that are important to call out for the initial PDL implementation.

Drugs on the Texas Medicaid formulary are designated as preferred, non-preferred, or neither designation. The PDL is a list of only drugs designated as preferred or non-preferred status. Most drugs are identified as preferred or non-preferred.  Drugs identified on the PDL as preferred, or not listed at all, are available to individuals without prior authorization.  Drugs identified as non-preferred require a PDL prior authorization.  In addition, clinical prior authorizations may apply to any individual drug or an entire drug class on the formulary, including some preferred and non-preferred drugs.

The PDL Criteria Guide (PDF) explains the criteria used to evaluate the PDL prior authorization requests, and will be updated by Jan. 29, 2018.

Drug Name Current status Jan 2018 status
Exelon Preferred Non-preferred
Memantine tablet Preferred Non-preferred
Rivastigmine Non-preferred Preferred
Suprax Preferred Non-preferred
Emflaza suspension and tablet Not previously reviewed Non-preferred
Farxiga (oral) Non-preferred Preferred
Invokamet XR (oral) Not previously reviewed Non-preferred
Invokamet (oral) Preferred Non-preferred
Invokana (oral) Preferred Non-preferred
Jardiance (oral) Non-preferred Preferred
Synjardy (oral) Non-preferred Preferred
Synjardy XR (oral) Not previously reviewed Non-preferred
Makena MDV Not previously reviewed Preferred
Makena SDV Not previously reviewed Preferred